newsfilter
← Latest News
Business Wire·

Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis and PORTOLA Phase 2a clinical trial evaluating zetomipzomib in autoimmune hepatitis are both open for enrollment KZR-261 dose